🇺🇸 FDA
Pipeline program

VEN (Venetoclax)

2025-HS-061

Phase 2 small_molecule active

Quick answer

VEN (Venetoclax) for Myelodysplastic Neoplasms is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Myelodysplastic Neoplasms
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials